Physician profile
Simon Peter Crass
NPI 1336450766
$6,041.70
in general payments reported to CMS, 2019-2025
25 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $367 · 2021: $91.47 · 2022: $2,267 · 2023: $663 · 2024: $1,024 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,800.23 | 2019-2025 | Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $1,009.10 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $330.19 | 2024-2025 | Omvoh |
| Celgene Corporation | $201.54 | 2021-2024 | Zeposia |
| Pfizer INC. | $141.55 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $101.40 | 2025 | Dupixent |
| Gilead Sciences, INC. | $69.03 | 2025 | |
| Janssen Biotech, INC. | $57.18 | 2022-2023 | Stelara, Simponi, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $36.48 | 2019-2023 | Linzess |
| Pharming Healthcare, INC. | $34.57 | 2023 | Ruconest |
| Medtronic, INC. | $33.84 | 2025 | Interstim |
| Madrigal Pharmaceuticals | $30.77 | 2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $20.90 | 2022 | |
| Daiichi Sankyo INC. | $20.63 | 2020 | |
| Alfasigma USA, INC. | $18.56 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $18.54 | 2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $17.30 | 2022 | |
| Genzyme Corporation | $16.84 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $15.09 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.09 | 2024 | |
| Allergan, INC. | $14.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.84 | 2019 | |
| Ardelyx, INC. | $13.61 | 2025 | Ibsrela |
| Echosens North America, INC. | $12.38 | 2025 | Fibroscan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Crass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.